ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0044

COVID-19 Seropositivity in New York ESKD Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Chand, Ranjeeta, New York University, New York, New York, United States
  • Charytan, David M., New York University, New York, New York, United States
  • Nazzal, Lama, New York University, New York, New York, United States
  • Mishra, Arnav, New York University, New York, New York, United States
  • Mehta, Mansi, New York University, New York, New York, United States
  • Holzman, Robert, New York University, New York, New York, United States

Group or Team Name

  • NYU Grossman School of Medicine, Division of Nephrology, New york
Background

Patients on hemodialysis (HD) with COVID-19 infections have increased emergency room visits, hospitalization, and mortality. We evaluated COVID-19 seroprevalence in a dialysis organization in NYC.

Methods

We collected data on patients undergoing maintenance HD in four different units in Manhattan, New York. Data was collected regarding demographics, cause of kidney failure, time on dialysis, and insurance. Covid antibody was tested using the elecsys Anti-SARS-CoV-2 immunoassay. We performed univariate analysis using Chi square test and multivariate linear logistic regression models to identify variables associated with COVID-19 seropositivity.

Results

Seropositivity was detected in 108 (20.2%) out of the 535 patients tested. In univariate analysis, age, HD unit, race, institutionalized status, time on dialysis, and type of insurance were associated with seropositivity. In multivariate analysis race, age, time on dialysis were not associated with COVID seropositivity Patients uninsured, or those covered by medicaid, had a significantly higher likelihood of testing positive for COVID antibodies than patients covered by private insurance (OR, 8.02, P=0.05). In reference to the Chinatown unit, patients receiving treatment at the 34th Street unit (OR, 4.90, p=0.002) and the Lower Manhattan unit (OR, 3.42, p=.02) were more likely to test positive., Institutionalized patients were almost eleven times more likely to test positive for the antibodies than those not institutionalized (OR, 10.97, p<0.001).
Race was not significantly associated with antibody positivity.

Conclusion

Our study showed increased prevalence of COVID-19 antibodies in Institutionalized and uninsured/Medicaid patients but no association with race suggesting socioeconomic status, is more important than race in determining the risk of COVID-19 infection in patients on maintenance dialysis.